C
페니트리움바이오
187660KOSDAQ자연과학 및 공학 연구개발업49.0 / 100
Reference Date: 2026-04-13
Financial Score17.5 / 40
News Sentiment12.5 / 25
Momentum7.0 / 20
Disclosure12.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but Revenue is on a declining trend. Plunged 20.1% over the past month, and news sentiment is neutral.
Company InformationBased on 2025 Annual Report
Business Overview
Penitrium Bio operates as a Contract Research Organization (CRO), providing comprehensive clinical trial services to pharmaceutical companies and biotech ventures, leveraging AI and big data for digital clinical trial technologies. The company also conducts Phase IV clinical trials to monitor drug safety and efficacy post-market approval and develops oncology treatments through its biotech business.
Number of Employees
110people
Average Salary
72.6M KRW
Score Calculation Basis
Detailed Financial Score
PER
—Industry Average 120.074.0Point
PBR
—Industry Average 3.823.5Point
ROE
-105.34Industry Average -32.113.5Point
3.3x industry avg (excellent)
Debt Ratio
3.59Industry Average 7.526.5Point
Half of industry avg (excellent)
Trend 2023~20250.0 / 10 points
Revenue Growth Rate
0.0 / 3
Avg ▼17.1% (2-year basis)
Operating Profit Growth Rate
0.0 / 3
Avg ▼153.1% (2-year basis)
ROE Trend
0.0 / 4
Avg ROE -79.0% (declining, 3yr)
Detailed News Sentiment
5 totalPositive 0Neutral 0Negative 0
- Neutral
- Neutral
- Neutral
Detailed Momentum
52-week position6.0Point
52w upper range (77%)
Current 14,810Won52-week high 18,67052-week low 1,135
1-month return0.0Point
1m -20.12% (strong drop)
Volume trend1.0Point
Volume decreasing
Detailed Disclosure
2 totalPositive 1Neutral 1Negative 0
- Neutral주식등의대량보유상황보고서(일반)2026-03-26
- Positive[기재정정]단일판매ㆍ공급계약체결2026-03-17